Celldex Therapeutics (CLDX) Intangibles (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Intangibles of $27.2 million for Q1 2026, little changed year-over-year from $27.2 million in Q1 2025, and little changed quarter-over-quarter from $27.2 million in Q4 2025.
Celldex Therapeutics (CLDX) Intangibles (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Intangibles history runs 17 years deep, the most recent figure standing at $27.2 million for Q1 2026.
- In Q1 2026, Intangibles changed 0.0% year-over-year to $27.2 million; the TTM figure through Mar 2026 stood at $27.2 million (changed 0.0% YoY), while the FY2025 annual figure was $27.2 million, changed 0.04% from the prior year.
- Intangibles for Q1 2026 stood at $27.2 million, roughly flat from $27.2 million in the prior quarter.
- The five-year high for Intangibles was $27.2 million in Q2 2022, with the low at $27.2 million in Q1 2022.
- The 5-year median for Intangibles is $27.2 million (2022), against an average of $27.2 million.
- Peak annual rise in Intangibles reached 0.04% in 2022, while the deepest fall reached 11.43% in 2022.
- Celldex Therapeutics' Intangibles stood at $27.2 million in 2022, then changed by 0.0% to $27.2 million in 2023, then changed by 0.0% to $27.2 million in 2024, then decreased by 0.04% to $27.2 million in 2025, then changed by 0.0% to $27.2 million in 2026.
- Business Quant data shows CLDX's Intangibles at $27.2 million in Q1 2026, $27.2 million in Q4 2025, and $27.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 27.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.20 Mn |
| Mar 31, 2026 | 27.19 Mn |
| Dec 31, 2025 | 27.19 Mn |
| Sep 30, 2025 | 27.19 Mn |
| Jun 30, 2025 | 27.19 Mn |
| Mar 31, 2025 | 27.19 Mn |
| Dec 31, 2024 | 27.20 Mn |
| Sep 30, 2024 | 27.19 Mn |
| Jun 30, 2024 | 27.19 Mn |
| Mar 31, 2024 | 27.19 Mn |
| Dec 31, 2023 | 27.20 Mn |
| Sep 30, 2023 | 27.20 Mn |
| Jun 30, 2023 | 27.19 Mn |
| Mar 31, 2023 | 27.19 Mn |
| Dec 31, 2022 | 27.20 Mn |
| Sep 30, 2022 | 27.19 Mn |
| Jun 30, 2022 | 27.20 Mn |
| Mar 31, 2022 | 27.19 Mn |
| Dec 31, 2021 | 27.19 Mn |
| Sep 30, 2021 | 27.20 Mn |